Looking to read the full article? Subscribe to BioWorld Asia.

Chinese investors launch new AU$45M fund to develop South Australian biotech

December 17, 2019

PERTH, Australia – Private Chinese investors have launched a new AU$45 million (US$31.17 million) investment fund to accelerate the development and commercialization of new biotechnology from South Australia for the global market.

Australia China BioWorld Asia Financings

Already a subscriber? Sign in

CNBG reports 100% seroconversion rate for COVID-19 vaccine candidate

BioWorld

BEIJING – Chinese state-backed vaccine developer China National Biotec Group (CNBG), of Beijing, said on Tuesday night that its inactivated COVID-19 vaccine...

Today's news in brief

BioWorld

BioWorld briefs for July 8.

Gloved hand holding COVID-19 vaccine vial, syringe

South Korea’s Genexine begins phase I/IIa trials for COVID-19 vaccine

BioWorld

HONG KONG – South Korea-based Genexine Inc. has started enrolling a phase I/II trial for a DNA vaccine targeting COVID-19 called GX-19.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for July 8.

Astrazeneca to give 400M COVID-19 vaccine doses to Europe; data expected August/September

BioWorld

LONDON - The EU has secured a supply of the most advanced COVID-19 vaccine in development, in a deal with Astrazeneca plc for up to 400 million doses of AZD-1222,...